To compare EI with needle injection through these conventional routes, we used a formalin-inactivated Aichi/68 influenza virus to immunize BALB/c mice (n = 8 per group). For EI, the vaccine was ...

Vaxxas, a clinical-stage biotechnology company, today announced it has secured a new patent from the United States patent office covering proprietary manufacturing technology for its novel vaccination ...